fda semaglutide shortage ends as sets deadline for compounders FDA warns about compounded versions

People with sensitive digestive systems should start with low doses or avoid berberine-containing products entirely

These details help clinicians decide whether to pause dose escalation, switch compounds (e.g., to tirzepatide or the Microdose Protocol), or introduce GI support strategies like dietary fiber timing or hydration adjustments

Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway

Researchers following protocols for weaning off tirzepatide who are planning to maintain berberine through the transition should be aware that blood glucose may rise as tirzepatide is reduced, potentially requiring upward berberine dose adjustment to maintain metabolic targets